Erectile dysfunction and cardiovascular risk factors.

Area of Science:

• Cardiology
• Urology
• Pharmacology

Background:

• Erectile dysfunction (ED) impacts a significant portion of the male population in the US.
• The risk factors associated with ED overlap considerably with those of atherosclerotic heart disease.
• A proactive approach by physicians is crucial for identifying both conditions.

Purpose of the Study:

• To highlight the connection between erectile dysfunction and cardiovascular disease.
• To emphasize the importance of screening for ED in men with cardiovascular disease and vice versa.
• To inform about the therapeutic options for ED, specifically oral sildenafil.

Main Methods:

• Clinical observation and risk factor analysis.
• Physician-led patient screening protocols.
• Pharmacological evaluation of sildenafil efficacy and contraindications.

Main Results:

• Erectile dysfunction affects up to 30 million men in the United States.
• Shared risk factors exist between ED and atherosclerotic heart disease.
• Oral sildenafil demonstrates efficacy in treating both organic and psychogenic ED.

Conclusions:

• Physicians should routinely inquire about ED in male patients, especially those with existing cardiovascular disease.
• Men diagnosed with ED should be evaluated for cardiovascular risk factors.
• Sildenafil is a viable treatment for ED but is contraindicated for patients using organic nitrates.